CVS Health is the most challenged of the managed care peers, with Aetna Medicare Advantage star ratings issues, PBM scrutiny, and retail pharmacy structural decline all compounding pressure. Activist Glenview engaged but turnaround pathway is multi-year. Retail pharmacy footprint optimization continues to drag. Oak Street Health primary care integration is the long-term thesis but execution has been mixed. Risk-reward unattractive until inflection visible.
Thesis reviewed May 29, 2026
CVS Health Corporation is headquartered in United States, which is currently showing elevated risk signals.
🇺🇸United States82EXITView United States risk detail →🏥Healthcare33NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| CVS | CVS Health Corporation | 40 | +15% | ↓3% | AVOID |
| HCA | HCA Healthcare Inc. | 40 | +9% | ↓3% | EARLY |
| UNH | UnitedHealth Group Inc. | 37 | +16% | ↓3% | AVOID |
| TMO | Thermo Fisher Scientific Inc. | 37 | +11% | ↓3% | EARLY |
| CI | The Cigna Group | 37 | +9% | ↓3% | NEUTRAL |
| ELV | Elevance Health Inc. | 37 | +7% | ↓3% | NEUTRAL |
| TEVA | Teva Pharmaceutical Industries Ltd. | 37 | +9% | ↓3% | NEUTRAL |
Investors who hold CVS may also have indirect exposure through these country funds.
CVS Aetna MA star ratings remain pressured, impacts 2026 bonuses
CVS announces 900 retail pharmacy closures over 3 years
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Alan Armstrong | Buy | $1k–$15k | Mar 27, 26 | ||
| Dwight EvansPA | D | Sell | $1k–$15k | Nov 21, 25 | -5.1% |
| John Boozman | Buy | $1k–$15k | Jan 29, 26 | +16.9% | |
| Thomas R. SuozziNY | D | Buy | $1k–$15k | Oct 24, 24 | +78.6% |
| Thomas H Tuberville | Sell | $1k–$15k | Aug 26, 24 | +68.3% | |
| Earl BlumenauerOR | Buy | $1k–$15k | Jun 27, 24 | +74.3% |